The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 43, Issue 4, 2014, Pages 1115-1136

  Bedse, Gaurav ^a   Romano, Adele ^a   Lavecchia, Angelo M ^a   Cassano, Tommaso ^b   Gaetani, Silvana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

2 AG; Alzheimer's disease; amyloid ; anandamide; cannabinoids; CB1; CB2; FAAH; MAGL; tau

Indexed keywords

AMYLOID BETA PROTEIN; CANNABINOID; ENDOCANNABINOID;

ALZHEIMER DISEASE; CELL ACTIVITY; GLIA CELL; HUMAN; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DRUG EFFECTS; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; BRAIN; ENDOCANNABINOIDS; HUMANS;

EID: 84919948769     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141635     Document Type: Review

References (194)

1. Wortmann M (2012) Dementia: A global health priority-highlights from an ADI and World Health Organization report. Alzheimers Res Ther 4, 40.
2. Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology 76 Part A, 27-50.
3. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415-418.
4. Walther S, Mahlberg R, Eichmann U, Kunz D (2006) Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 185, 524-528.
5. Maroof N, Pardon MC, Kendall DA (2013) Endocannabinoid signalling in Alzheimer's disease. Biochem Soc Trans 41, 1583-1587.
6. Karl T, Cheng D, Garner B, Arnold JC (2012) The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert Opin Ther Targets 16, 407-420.
7. Bisogno T, Di Marzo V (2008) The role of the endocannabinoid system in Alzheimer's disease: Facts and hypotheses. Curr Pharm Des 14, 2299-3305.
8. Aso E, Ferrer I (2014) Cannabinoids for treatment of Alzheimer's disease: Moving toward the clinic. Front Pharmacol 5, 37.
9. D' Addario C, Di Francesco A, Trabace L, Finazzi Agro A, Cuomo V, Maccarrone M (2013) Endocannabinoid signaling in Alzheimers disease: Current knowledge and future directions. J Biol Regul Homeost Agents 27, 61-73.
10. Fagan SG, Campbell VA (2014) The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol 171, 1347-1360.
11. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
12. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27, 457-464.
13. Selkoe DJ (1989) Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. Cell 58, 611-612.
14. Iqbal K, Grundke-Iqbal I (2002) Neurofibrillary pathology leads to synaptic loss and not the other way around in Alzheimer disease. J Alzheimers Dis 4, 235-238.
15. Beach TG, Walker R, McGeer EG (1989) Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 2, 420-436.
16. Rogers J, Luber-Narod J, Styren SD, Civin WH (1988) Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9, 339-349.
17. LaFerlaFM(2010) Pathways linking Abeta and tau pathologies. Biochem Soc Trans 38, 993-995.
18. Cruts M, Van Broeckhoven C (1998) Molecular genetics of Alzheimer's disease. Ann Med 30, 560-565.
19. Crews L, Masliah E (2010) Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 19, R12-R20.
20. Klein WL (2013) Synaptotoxic amyloid-beta oligomers: A molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J Alzheimers Dis 33 Suppl 1, S49-S65.
21. Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci 24, 219-224.
22. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11, 213-228.
23. Mukhamedyarov MA, Zefirov AL (2013) The influence of beta-amyloid peptide on the functions of excitable tissues: Physiological and pathological aspects. Usp Fiziol Nauk 44, 55-71.
24. Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193.
25. McGeer PL, McGeer EG, Yasojima K (2000) Alzheimer disease and neuroinflammation. J Neural Transm Suppl 59, 53-57.
26. Streit WJ (2004) Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 77, 1-8.
27. Munoz L, Ammit AJ (2010) Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 58, 561-568.
28. Shigematsu K, McGeer PL,Walker DG, Ishii T, McGeer EG (1992) Reactive microglia/macrophages phagocytose amyloid precursor protein produced by neurons following neural damage. J Neurosci Res 31, 443-453.
29. Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE (1999) Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J Neurosci 19, 928-939.
30. Sondag CM, Dhawan G, Combs CK (2009) Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation 6, 1.
31. SastreM,KlockgetherT, HenekaMT(2006) Contribution of inflammatory processes to Alzheimer's disease: Molecular mechanisms. Int J Dev Neurosci 24, 167-176.
32. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ (2005) Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18, 459-465.
33. Arroyo DS, Soria JA, Gaviglio EA, Rodriguez-Galan MC, Iribarren P (2011) Toll-like receptors are key players in neurodegeneration. Int Immunopharmacol 11, 1415-1421.
34. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE (2009) CD14 and toll-like receptors 2 and 4 are required for fibrillarA{beta}-stimulated microglial activation. J Neurosci 29, 11982-11992.
35. Izumi Y, Tokuda K, Zorumski CF (2008) Long-term potentiation inhibition by low-level N-methyl-D-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase. Hippocampus 18, 258-265.
36. Moult PR, Correa SA, Collingridge GL, Fitzjohn SM, Bashir ZI (2008) Co-activation of p38 mitogen-activated protein kinase and protein tyrosine phosphatase underlies metabotropic glutamate receptor-dependent long-term depression. J Physiol 586, 2499-2510.
37. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4, 873-884.
38. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83, 1017-1066.
39. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
40. SugiuraT,Kondo S, SukagawaA, Nakane S, Shinoda A, Itoh K,Yamashita A,WakuK(1995) 2-Arachidonoylglycerol:A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215, 89-97.
41. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50, 83-90.
42. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
43. Sugiura T, Kondo S, Sukagawa A, Tonegawa T, Nakane S, Yamashita A, Waku K (1996) Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: Involvement of Ca(2+)-dependent transacylase and phosphodiesterase activities. Biochem Biophys Res Commun 218, 113-117.
44. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, Kunos G (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264, 258-267.
45. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23, 1398-1405.
46. Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, Bes-Houtmann S, Rouch C, Robert-Da Silva C, Chesne S, Lefebvre d'Hellencourt C, Cesari M, Di Marzo V, Roche R (2007) Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) 15, 837-845.
47. Gauthier KM, Baewer DV, Hittner S, Hillard CJ, Nithipatikom K, Reddy DS, Falck JR, CampbellWB(2005) Endothelium-derived 2-arachidonylglycerol: An intermediate in vasodilatory eicosanoid release in bovine coronary arteries. Am J Physiol Heart Circ Physiol 288, H1344-H1351.
48. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K (2000) Evidence that 2-arachidonoylglycerol but not Npalmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275, 605-612.
49. Maccarrone M, Dainese E, Oddi S (2010) Intracellular trafficking of anandamide: New concepts for signaling. Trends Biochem Sci 35, 601-608.
50. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
51. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232, 54-61.
52. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
53. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006) Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res 1071, 10-23.
54. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P, Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfitz L, Uhl GR (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074, 514-536.
55. Ashton JC, Friberg D, Darlington CL, Smith PF (2006) Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study. Neurosci Lett 396, 113-116.
56. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332.
57. Atwood BK, MackieK(2010) CB2:Acannabinoid receptor with an identity crisis. Br J Pharmacol 160, 467-479.
58. Lou ZY, Chen C, He Q, Zhao CB, Xiao BG (2011) Targeting CB(2) receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis. Mol Immunol 49, 453-461.
59. Stella N (2009) Endocannabinoid signaling in microglial cells. Neuropharmacology 56 (Suppl 1), 244-253.
60. Cabral GA, Griffin-Thomas L (2009) Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. Expert Rev Mol Med 11, e3.
61. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2). Pharmacol Rev 62, 588-631.
62. Pertwee RG (2007) GPR55: A new member of the cannabinoid receptor clan? Br J Pharmacol 152, 984-986.
63. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: A heatactivated ion channel in the pain pathway. Nature 389, 816-824.
64. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87.
65. Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, BahrBA(2010) Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality. Life Sci 86, 615-623.
66. Goparaju SK, Ueda N, Taniguchi K, Yamamoto S (1999) Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57, 417-423.
67. Castillo Pablo E, Younts Thomas J, Chávez Andrés E, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76, 70-81.
68. Chavez AE, Chiu CQ, Castillo PE (2010) TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci 13, 1511-1518.
69. Brailoiu GC, Oprea TI, Zhao P, Abood ME, Brailoiu E (2011) Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J Biol Chem 286, 29166-29174.
70. Rozenfeld R, Devi LA (2008) Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3.FASEB J 22, 2311-2322.
71. Benard G, Massa F, Puente N, Lourenco J, Bellocchio L, Soria-Gomez E, Matias I, Delamarre A, Metna-Laurent M, Cannich A, Hebert-Chatelain E, Mulle C, Ortega-Gutierrez S, Martin-Fontecha M, Klugmann M, Guggenhuber S, Lutz B, Gertsch J, Chaouloff F, Lopez-Rodriguez ML, Grandes P, Rossignol R, Marsicano G (2012) Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci 15, 558-564.
72. Hopper MW, Vogel FS (1976) The limbic system in Alzheimer's disease. A neuropathologic investigation. Am J Pathol 85, 1-20.
73. Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol, 299-325.
74. Pazos MR, Nunez E, Benito C, Tolon RM, Romero J (2004) Role of the endocannabinoid system in Alzheimer's disease: New perspectives. Life Sci 75, 1907-1915.
75. Koppel J, Davies P (2008) Targeting the endocannabinoid system in Alzheimer's disease. J Alzheimers Dis 15, 495-504.
76. Benito C, Nunez E, Pazos MR, Tolon RM, Romero J (2007) The endocannabinoid system and Alzheimer's disease. Mol Neurobiol 36, 75-81.
77. CampbellVA,GowranA(2007) Alzheimer's disease; taking the edge off with cannabinoids? Br J Pharmacol 152, 655-662.
78. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63, 637-652.
79. Benito C, Nunez E,TolonRM,Carrier EJ, Rabano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23, 11136-11141.
80. Mulder J, Zilberter M, Pasquare SJ, Alpar A, Schulte G, Ferreira SG, Kofalvi A, Martin-Moreno AM, Keimpema E, Tanila H,Watanabe M, Mackie K, HortobagyiT, de Ceballos ML, Harkany T (2011) Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 134, 1041-1060.
81. Lee JH, Agacinski G,Williams JH,Wilcock GK, Esiri MM, Francis PT, Wong PT, Chen CP, Lai MK (2010) Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochem Int 57, 985-989.
82. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML (2005) Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 25, 1904-1913.
83. Solas M, Francis PT, Franco R, Ramirez MJ (2013) CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol Aging 34, 805-808.
84. Farkas S, Nagy K, Palkovits M, Kovács GG, Jia Z, Donohue S, Pike V, Halldin C, Máthé D, Harkany T, Gulyás B, Csiba L (2012) [1251] SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease. Neurochem Int 60, 286-291.
85. Bedse G, Romano A, Cianci S, Lavecchia AM, Lorenzo P, Elphick MR, Laferla FM, Vendemiale G, Grillo C, Altieri F, Cassano T, Gaetani S (2014) Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 40, 701-712.
86. Kalifa S, Polston EK, Allard JS, Manaye KF (2011) Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe/PS1DeltaE9 double transgenic mice. Brain Res 1376, 94-100.
87. Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, Di Marzo V, Steardo L (2007) Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: In vitro and in vivo evidence. J Pharmacol Exp Ther 322, 1144-1152.
88. Ahmad R, Goffin K, Van den Stock J, De Winter F-L, Cleeren E, Bormans G, Tournoy J, Persoons P, Van Laere K, VandenbulckeM(2014) In vivo type 1 cannabinoid receptor availability in Alzheimer's disease. Eur Neuropsychopharmacol 24, 242-250.
89. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its agedependent decline in mice. Proc Natl Acad Sci U S A 100, 1393-1398.
90. Manuel I, Gonzalez de San Roman E, Giralt MT, Ferrer I, Rodriguez-Puertas R (2014) Type-1 cannabinoid receptor activity during Alzheimer's disease progression. J Alzheimers Dis 42, 761-766.
91. Halleskog C, Mulder J, Dahlstrom J, Mackie K, Hortobagyi T, Tanila H, Kumar Puli L, Farber K, Harkany T, Schulte G (2011) WNT signaling in activated microglia is proinflammatory. Glia 59, 119-131.
92. Grunblatt E, Zander N, Bartl J, Jie L, Monoranu CM, Arzberger T, Ravid R, RoggendorfW, Gerlach M, Riederer P (2007) Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. J Alzheimers Dis 12, 291-311.
93. Jung KM, Astarita G, Yasar S, Vasilevko V, Cribbs DH, Head E, CotmanCW, PiomelliD(2012) An amyloid beta42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol Aging 33, 1522-1532.
94. Nunez E, Benito C, Pazos MR, Barbachano A, Fajardo O, Gonzalez S, Tolon RM, Romero J (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study. Synapse 53, 208-213.
95. Nunez E, Benito C, Tolon RM, Hillard CJ, Griffin WS, Romero J (2008) Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloidlinked events in Down's syndrome. Neuroscience 151, 104-110.
96. Horti AG, Gao Y, Ravert HT, Finley P, Valentine H, Wong DF, Endres CJ, Savonenko AV, Dannals RF (2010) Synthesis and biodistribution of [11C] A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem 18, 5202-5207.
97. Grunblatt E, Bartl J, Zehetmayer S, Ringel TM, Bauer P, Riederer P, Jacob CP (2009) Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis 16, 627-634.
98. Koppel J, BradshawH, Goldberg TE, Khalili H, Marambaud P, Walker MJ, Pazos M, Gordon ML, Christen E, Davies P (2009) Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: A case-control and cohort study. Lipids Health Dis 8, 2.
99. Piro JR, Benjamin DI, Duerr JM, Pi Y, Gonzales C, Wood KM, Schwartz JW, Nomura DK, Samad TA (2012) A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep 1, 617-623.
100. Farooqui AA, Liss L, Horrocks LA (1988) Neurochemical aspects of Alzheimer's disease: Involvement of membrane phospholipids. Metab Brain Dis 3, 19-35.
101. van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V (2006) Endocannabinoids and beta-amyloidinduced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63, 1410-1424.
102. Campillo NE, Paez JA (2009) Cannabinoid system in neurodegeneration: New perspectives in Alzheimer's disease. Mini Rev Med Chem 9, 539-559.
103. Micale V, Mazzola C, Drago F (2007) Endocannabinoids and neurodegenerative diseases. Pharmacol Res 56, 382-392.
104. Ruiz-Valdepeñas L, Benito C, Tolón RM, Martínez Orgado JA, Romero J (2010) The endocannabinoid system and amyloid-related diseases. Exp Neurol 224, 66-73.
105. Bilkei-Gorzo A (2012) The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci 367, 3326-3341.
106. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28, 8354-8360.
107. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytle RD (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2, 29.
108. Tolón RM, Núñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA, Romero J (2009) The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res 1283, 148-154.
109. Janefjord E, Maag JL, Harvey BS, SmidSD(2014) Cannabinoid effects on beta amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell Mol Neurobiol 34, 31-42.
110. Koppel J,VingtdeuxV, Marambaud P, d'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P (2013) CB(2) receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Mol Med 19, 357-364.
111. Stumm C, Hiebel C, Hanstein R, Purrio M, Nagel H, Conrad A, Lutz B, Behl C, Clement AB (2013) Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Neurobiol Aging 34, 2574-2584.
112. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D (2013) Role of the cannabinoid system in the transit of betaamyloid across the blood-brain barrier. Mol Cell Neurosci 56, 255-262.
113. Gauthier A, Vassiliou G, Benoist F, McPherson R (2003) Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. J Biol Chem 278, 11945-11953.
114. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptorrelated protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
115. Chen R, Zhang J, Wu Y, Wang D, Feng G, Tang YP, Teng Z, Chen C (2012) Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep 2, 1329-1339.
116. Duan Y, Dong S, Gu F, Hu Y, Zhao Z (2012) Advances in the pathogenesis of Alzheimer's disease: Focusing on taumediated neurodegeneration. Transl Neurodegener 1, 24.
117. Churcher I (2006) Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr Top Med Chem 6, 579-595.
118. Rohn TT (2010) The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. Apoptosis 15, 1403-1409.
119. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL (2003) Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100, 10032-10037.
120. Saez TE, Pehar M, Vargas M, Barbeito L, Maccioni RB (2004) Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo 18, 275-280.
121. Esposito G, De Filippis D, Steardo L, Scuderi C, Savani C, Cuomo V, Iuvone T (2006) CB1 receptor selective activa tion inhibits amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett 404, 342-346.
122. Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T (2006) The marijuana component cannabidiol inhibits betaamyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med (Berl) 84, 253-258.
123. Sperber BR, Leight S, Goedert M, Lee VM (1995) Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett 197, 149-153.
124. Cao C, Li Y, Liu H, Bai G, Mayl J, Lin X, Sutherland K, Nabar N, JianfengC(2014) The potential therapeutic effects of THC on Alzheimer's disease. J Alzheimers Dis 42, 973-984.
125. Chami L, Checler F (2012) BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer's disease. Mol Neurodegener 7, 52.
126. Howlett AC, Mukhopadhyay S, Norford DC (2006) Endocannabinoids and reactive nitrogen and oxygen species in neuropathologies. J Neuroimmune Pharmacol 1, 305-316.
127. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E (2005) CB1 cannabinoid receptors are involved in neuroprotection via NF-kappaBinhibition. J Cereb Blood Flow Metab 25, 477-484.
128. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, Shohami E (2006) The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22, 257-264.
129. Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M (2013) Activation of the CB2 receptor system reverses amyloidinduced memory deficiency. Neurobiol Aging 34, 791-804.
130. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54, 161-202.
131. Martin-Moreno AM, Reigada D, Ramirez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer's disease. Mol Pharmacol 79, 964-973.
132. Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Steardo L (2007) Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 151, 1272-1279.
133. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carratu MR, Iuvone T, Steardo L (2011) Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS One 6, e28668.
134. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1betastimulated human astrocytes. Glia 49, 211-219.
135. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T (2006) Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in amyloid stimulated PC12 neurons through p38 MAP kinase and NF-B involvement. Neurosci Lett 399, 91-95.
136. Xu JY, Chen C (2014) Endocannabinoids in synaptic plasticity and neuroprotection. Neuroscientist. doi: 10.1177/1073858414524632
137. Benito C, Tolon RM, Castillo AI, Ruiz-Valdepenas L, Martinez-Orgado JA, Fernandez-Sanchez FJ, Vazquez C, Cravatt BF, Romero J (2012) beta-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-alpha, PPAR-gamma and TRPV1, but not CB(1) or CB(2) receptors. Br J Pharmacol 166, 1474-1489.
138. Gervois P, Mansouri RM (2012) PPARalpha as a therapeutic target in inflammation-associated diseases. Expert Opin Ther Targets 16, 1113-1125.
139. Piomelli D, Sasso O (2014) Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci 17, 164-174.
140. Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A (2012) WIN55212-2 attenuates amyloid-betainduced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-gamma pathway. Neuropharmacology 63, 653-666.
141. Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML (2012) Prolonged oral cannabinoid administration prevents neuroinflammation, lowers betaamyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 9, 8.
142. Alhouayek M, Muccioli GG (2014) COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 35, 284-292.
143. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334, 809-813.
144. Zhang J, Chen C (2008) Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 283, 22601-22611.
145. Chen X, Zhang J, Chen C (2011) Endocannabinoid 2-arachidonoylglycerol protects neurons against beta-amyloid insults. Neuroscience 178, 159-168.
146. Du H, Chen X, Zhang J, Chen C (2011) Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-gamma. Br J Pharmacol 163, 1533-1549.
147. Hoshino T, Namba T, Takehara M, Murao N, Matsushima T, Sugimoto Y, Narumiya S, Suzuki T, Mizushima T (2012) Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP(4) receptor. J Neurochem 120, 795-805.
148. Noonan J, Tanveer R, Klompas A, Gowran A, McKiernan J, Campbell VA (2010) Endocannabinoids prevent beta-amyloid-mediated lysosomal destabilization in cultured neurons. J Biol Chem 285, 38543-38554.
149. Milton NG (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett 332, 127-130.
150. Harvey BS, Ohlsson KS, Maag JLV, Musgrave IF, Smid SD (2012) Contrasting protective effects of cannabinoids against oxidative stress and amyloid evoked neurotoxicity in vitro. Neurotoxicology 33, 138-146.
151. Haghani M, Shabani M, Javan M, Motamedi F, JanahmadiM( 2012) CB1 cannabinoid receptor activation rescues amyloid beta-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones. Cell Physiol Biochem 29, 391-406.
152. Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D (2005) Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 134, 261-268.
153. Cardenas A, Moro MA, Hurtado O, Leza JC, Lizasoain I (2005) Dual role of nitric oxide in adult neurogenesis. Brain Res Brain Res Rev 50, 1-6.
154. Butterfield DA, Sultana R (2011) Methionine-35 of abeta(1-42): Importance for oxidative stress in Alzheimer disease. J Amino Acid 2011, 198430.
155. Moncada S, Rees DD, Schulz R, Palmer RM (1991) Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A 88, 2166-2170.
156. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on betaamyloid-induced toxicity in PC12 cells. J Neurochem 89, 134-141.
157. Haas J, Storch-Hagenlocher B, Biessmann A, Wildemann B (2002) Inducible nitric oxide synthase and argininosuccinate synthetase: Co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro. Neurosci Lett 322, 121-125.
158. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95, 8268-8273.
159. Athanasiou A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith PA, Bagiokou D, Bradshaw TD, Westwell AD, Fang L, Lobo DN, Constantinescu CS, Calabrese V, Loesch A, Alexander SPH, Clothier RH, Kendall DA, Bates TE (2007) Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun 364, 131-137.
160. Chiu P, Karler R, Craven C, Olsen DM, Turkanis SA (1975) The influence of delta9-tetrahydrocannabinol, cannabinol and cannabidiol on tissue oxygen consumption. Res Commun Chem Pathol Pharmacol 12, 267-286.
161. Zaccagnino P, Corcelli A, Baronio M, Lorusso M (2011) Anandamide inhibits oxidative phosphorylation in isolated liver mitochondria. FEBS Lett 585, 429-434.
162. Velez-Pardo C, Jimenez-Del-Rio M, Lores-Arnaiz S, Bustamante J (2010) Protective effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain mitochondria upon paraquat exposure. Neurochem Res 35, 1323-1332.
163. Zaccagnino P, D'Oria S, Romano LL, Di Venere A, Sardanelli AM, Lorusso M (2012) The endocannabinoid 2-arachidonoylglicerol decreases calcium induced cytochrome c release from liver mitochondria. J Bioenerg Biomembr 44, 273-280.
164. Catanzaro G, Rapino C, Oddi S, Maccarrone M (2009) Anandamide increases swelling and reduces calcium sensitivity of mitochondria. Biochem Biophys Res Commun 388, 439-442.
165. Marsicano G, Lafenetre P (2009) Roles of the endocannabinoid system in learning and memory. Curr Top Behav Neurosci 1, 201-230.
166. Katona I, Freund TF (2008) Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14, 923-930.
167. Chen QS, Kagan BL, Hirakura Y, Xie CW (2000) Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 60, 65-72.
168. Orr AL, Hanson JE, Li D, Klotz A, Wright S, Schenk D, Seubert P, Madison DV (2014) beta-Amyloid inhibits E-S potentiation through suppression of cannabinoid receptor 1-dependent synaptic disinhibition. Neuron 82, 1334-1345.
169. Albayram O, Alferink J, Pitsch J, Piyanova A, Neitzert K, Poppensieker K, Mauer D, Michel K, Legler A, Becker A, Monory K, Lutz B, Zimmer A, Bilkei-Gorzo A (2011) Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging. Proc Natl Acad Sci U S A 108, 11256-11261.
170. Cheng D, Spiro AS, Jenner AM, Garner B, Karl T (2014) Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. J Alzheimers Dis 42, 1383-1396.
171. Aso E, Sánchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I (2014) Cannabis-based medicine reduces multiple pathological processes in APP/PS1 mice. J Alzheimers Dis 43, 977-991.
172. Chen B, Bromley-Brits K, He G, Cai F, Zhang X, Song W (2010) Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Curr Alzheimer Res 7, 255-261.
173. Mazzola C, Micale V, Drago F (2003) Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol 477, 219-225.
174. Francis PT, Palmer AM, Snape M,Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 66, 137-147.
175. Eubanks LM, Rogers CJ, Beuscher AEt, Koob GF, Olson AJ, Dickerson TJ, Janda KD (2006) A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 3, 773-777.
176. Gonzalez-Naranjo P, Campillo NE, Perez C, Paez JA (2013) Multitarget cannabinoids as novel strategy for Alzheimer disease. Curr Alzheimer Res 10, 229-239.
177. Nadler V, Mechoulam R, SokolovskyM(1993) Blockade of 45Ca2+ influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Brain Res 622, 79-85.
178. Eshhar N, Striem S, Biegon A (1993) HU-211, a nonpsychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 5, 237-240.
179. Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A (1995) Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 283, 19-29.
180. Woo HN, Park JS, Gwon AR, Arumugam TV, Jo DG (2009) Alzheimer's disease and Notch signaling. Biochem Biophys Res Commun 390, 1093-1097.
181. Bray SJ (2006) Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol 7, 678-689.
182. Costa RM, Honjo T, Silva AJ (2003) Learning and memory deficits in Notch mutant mice. Curr Biol 13, 1348-1354.
183. Tanveer R, Gowran A, Noonan J, Keating SE, Bowie AG, Campbell VA (2012) The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-beta and in the cortex of aged rats. J Biol Chem 287, 34709-34721.
184. Wagner JA, Járai Z, Bátkai S, Kunos G (2001) Hemodynamic effects of cannabinoids: Coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol 423, 203-210.
185. Ramirez SH, Hasko J, Skuba A, Fan S, Dykstra H, McCormick R, Reichenbach N, Krizbai I, Mahadevan A, Zhang M, Tuma R, Son YJ, Persidsky Y (2012) Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci 32, 4004-4016.
186. Ahn K, McKinney MK, Cravatt BF (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108, 1687-1707.
187. Martin BR, Compton DR, Little PJ, Martin TJ, Beardsley PM(1987) Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids. NIDA Res Monogr 79, 108-122.
188. Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schutz G,Wotjak CT, Lutz B, Marsicano G (2007) Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol 5, e269.
189. Viveros MP, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81, 331-342.
190. Moreira FA, Grieb M, Lutz B (2009) Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: Focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23, 133-144.
191. Karkkaine E, Tanila H, Laitinen JT (2012) Functional autoradiography shows unaltered cannabinoid CB1 receptor signalling in hippocampus and cortex of APP/PS1 transgenic mice. CNS Neurol Disord Drug Targets 11, 1038-1044.
192. D'Addario C, Di Francesco A, Arosio B, Gussago C, Dell'Osso B, Bari M, Galimberti D, Scarpini E, Altamura AC,Mari D, MaccarroneM(2012) Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One 7, e39186.
193. Maroof N, Ravipati S, Pardon MC, Barrett DA, Kendall DA (2014) Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the APPswe/PS1E9 mouse model of Alzheimer's disease. J Alzheimers Dis. doi: 10.3233/JAD-131961, in press.
194. Gifford AN, Bruneus M, Gatley SJ, Volkow ND (2000) Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Br J Pharmacol 131, 645-650.